[{"id":"4c91d9cf-6bbf-4c1f-969c-1a699ba5d11f","acronym":"FIOL","url":"https://clinicaltrials.gov/study/NCT03804580","created_at":"2021-01-18T18:48:20.019Z","updated_at":"2024-07-02T16:35:05.467Z","phase":"Phase 2","brief_title":"First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03804580 - FIOL","lead_sponsor":"Vestre Viken Hospital Trust","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-07"},{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"49bd229e-a7a9-42f3-9559-2510a8eb6543","acronym":"LUN 17-139","url":"https://clinicaltrials.gov/study/NCT03786692","created_at":"2021-01-18T18:43:52.417Z","updated_at":"2024-07-02T16:35:19.761Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC","source_id_and_acronym":"NCT03786692 - LUN 17-139","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-12"},{"id":"be744523-e7d4-4a11-8136-98abcc13428e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05704634","created_at":"2023-01-30T15:59:29.317Z","updated_at":"2024-07-02T16:35:21.406Z","phase":"Phase 1","brief_title":"A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05704634","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" STK11","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/18/2023","start_date":" 08/18/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-01-31"},{"id":"06bce804-bede-4084-9f43-37dffac91812","acronym":"CVL009-2001","url":"https://clinicaltrials.gov/study/NCT06029816","created_at":"2023-09-08T20:10:17.441Z","updated_at":"2024-07-02T16:35:37.650Z","phase":"Phase 2","brief_title":"Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations","source_id_and_acronym":"NCT06029816 - CVL009-2001","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2023-09-08"},{"id":"2f454d62-b561-48df-9aa8-c95f396adca9","acronym":"VOLFI","url":"https://clinicaltrials.gov/study/NCT01328171","created_at":"2021-01-18T05:24:48.418Z","updated_at":"2024-07-02T16:35:45.737Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","source_id_and_acronym":"NCT01328171 - VOLFI","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-06-14"},{"id":"a207107c-5cf5-44dd-9047-a177e4c44953","acronym":"","url":"https://clinicaltrials.gov/study/NCT05104281","created_at":"2021-11-02T17:57:16.744Z","updated_at":"2024-07-02T16:35:52.031Z","phase":"Phase 3","brief_title":"Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05104281","lead_sponsor":"Qingdao Central Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 21 mutation • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 21 mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-03-29"},{"id":"ee2f1151-0f4f-4a69-942e-a345a7a08618","acronym":"","url":"https://clinicaltrials.gov/study/NCT05497076","created_at":"2022-11-08T19:26:21.936Z","updated_at":"2024-07-02T16:36:05.643Z","phase":"","brief_title":"the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy","source_id_and_acronym":"NCT05497076","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation","tags":["CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-08-11"},{"id":"31455c2c-ff0c-44b3-849c-ae43fb5fde26","acronym":"EPICAL","url":"https://clinicaltrials.gov/study/NCT03623750","created_at":"2021-01-18T17:48:13.570Z","updated_at":"2024-07-02T16:36:07.996Z","phase":"Phase 1/2","brief_title":"E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C","source_id_and_acronym":"NCT03623750 - EPICAL","lead_sponsor":"Instituto Oncológico Dr Rosell","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CimaVax EGF (EGF-PTI) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 07/06/2018","start_date":" 07/06/2018","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2022-06-30"},{"id":"70cda564-24d2-415f-ad1c-352a0232a913","acronym":"","url":"https://clinicaltrials.gov/study/NCT01415011","created_at":"2021-01-18T05:49:31.913Z","updated_at":"2024-07-02T16:37:03.819Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients","source_id_and_acronym":"NCT01415011","lead_sponsor":"University College, London","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 11/30/2018","study_completion_date":" 11/30/2018","last_update_posted":"2019-01-15"},{"id":"aa7364cb-a6dc-4791-8997-3c26fb523699","acronym":"","url":"https://clinicaltrials.gov/study/NCT01310036","created_at":"2021-01-18T05:19:57.747Z","updated_at":"2024-07-02T16:37:06.980Z","phase":"Phase 2","brief_title":"A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations","source_id_and_acronym":"NCT01310036","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 04/30/2011","start_date":" 04/30/2011","primary_txt":" Primary completion: 02/14/2014","primary_completion_date":" 02/14/2014","study_txt":" Completion: 12/30/2016","study_completion_date":" 12/30/2016","last_update_posted":"2018-09-12"},{"id":"48e2de87-60f9-47a5-a81a-59b789c6b906","acronym":"","url":"https://clinicaltrials.gov/study/NCT03399669","created_at":"2021-01-18T16:46:39.567Z","updated_at":"2024-07-02T16:37:14.844Z","phase":"Phase 2","brief_title":"The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation","source_id_and_acronym":"NCT03399669","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 02/17/2015","start_date":" 02/17/2015","primary_txt":" Primary completion: 06/30/2018","primary_completion_date":" 06/30/2018","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2018-01-16"},{"id":"ab484842-6095-40fb-a5af-dd726c11e29a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074864","created_at":"2021-01-18T15:08:51.364Z","updated_at":"2024-07-02T16:37:24.595Z","phase":"Phase 2/3","brief_title":"Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC","source_id_and_acronym":"NCT03074864","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 02/27/2017","start_date":" 02/27/2017","primary_txt":" Primary completion: 06/30/2019","primary_completion_date":" 06/30/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2017-03-09"},{"id":"627bf09b-0c4c-47f9-99e8-7157199ed6f1","acronym":"LUX Lung 2","url":"https://clinicaltrials.gov/study/NCT00525148","created_at":"2021-01-17T17:11:46.906Z","updated_at":"2024-07-02T16:37:29.074Z","phase":"Phase 2","brief_title":"LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations","source_id_and_acronym":"NCT00525148 - LUX Lung 2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 129","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2016-09-16"}]